Trial
NCT04985968
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
InDex Pharmaceuticals
Collaborators
—
Condition
Ulcerative Colitis
Intervention
Cobitolimod 250 mg
Why stopped
Due to futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-27